Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 2, 2008, Pages 235-244

  Fei, Wen Lei ^a   Chen, Jia Qi ^a   Yuan, Jin ^a   Quan, Da Ping ^b   Zhou, Shi You ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD79 ANTIGEN; CD8 ANTIGEN; CHLORDANE; COPOLYMER; DEXAMETHASONE; EYE DROPS; INTERCELLULAR ADHESION MOLECULE 1; NANOSPHERE; PHOSPHATE BUFFERED SALINE; POLY(LACTIC CO GLYCOLIC ACID) COPOLYMER; TACROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PENETRATING KERATOPLASTY; RABBIT; RAT;

ANIMALS; CORNEA; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; LACTIC ACID; NANOSPHERES; OPHTHALMIC SOLUTIONS; POLYGLYCOLIC ACID; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TACROLIMUS; TIME FACTORS;

EID: 41349103066     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0059     Document Type: Article

References (29)

1. Inoue, K., Amano, S., Oshika, T., et al. Risk factors for corneal graft failure and rejection in penetrating keratoplasty. Acta. Ophthalmol. Scand. 79:251-255, 2001.
2. Larkin, D.F. Corneal allograft rejection. Br. J. Ophthalmol. 78:649-652, 1994.
3. Jonas, J.B., Rank, R.M., and Budde, W.M. Immunologic graft reactions after allogenic penetrating keratoplasty. Am. J. Ophthalmol. 133:437-443, 2002.
4. Starzl, T.E., Todo, S., Fung, J., et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 2:1000-1004, 1989.
5. Nishi, M., Herbort, C.P., Matsubara, M., et al. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest. Ophthalmol. Vis. Sci. 34:2477-2486, 1993.
6. Sloper, C.M., Powell, R.J., and Dua, H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723-728, 1999.
7. Kino, T., Hatanaka, H., Hashimoto, M., et al. FK506, a novel immunosuppressant isolated from a Streptomyces, fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 9:1249-1255, 1987.
8. Shapiro, R., Fung, J.J., Jain, A.B., et al. The side effects of FK506 in humans. Transpl. Proc. 22(Suppl. 1):35-36, 1990.
9. Mills, R.A., Jones, D.B., Winkler, C.R., et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea 14:157-160, 1995.
10. Hikita, N., Lopez, J.S., Chan, C.C., et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest. Ophthalmol. Vis. Sci. 38:901-909, 1997.
11. Dickey, J.B., Cassidy, E.M., and Bouchard, C.S. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea 12:204-207, 1993.
12. Okada, K., Sakata, H., Minamoto, A., et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 210:175-179, 1996.
13. Mochizuki, M., Ikeda, E., Shirao, M., et al. Preclinical and clinical study of FK506 in uveitis. Curr. Eye Res. 11(Suppl.):87-95, 1992.
14. Xie, H., Chen, J., Lin, Y., et al. Effect of FK506 eyedrop combined with keratoplasty on recurrent Mooren's ulcer. Chin. J. Ophtaalmol. 38:13-15, 2002.
15. Mayer, K., Reinhard, T., Reis, A., et al. FK506 ointment 0.1% - a new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin. Monatsbl. Augenheilkd. 218:733-736, 2001.
16. Sengoku, T., Sakuma, S., Satoh, S., et al. Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin. Exp. Allergy 33:1555-1560, 2003.
17. Hall, V.C., Liesegang, T.J., Kostick, D.A., et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch. Dermatol. 139:1083-1084, 2003.
18. Pleyer, U., Lutz, S., Jusko, W.J., et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 34:2737-2742, 1993.
19. Allen, C., Yu, Y., Maysinger, D., et al. Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. Bioconjug. Chem. 9:564-572, 1998.
20. Yura, H., Yoshimura, N., Hamashima, T., et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. J. Contr. Rel. 57:87-99, 1999.
21. Whitcup, S.M., Pleyer, U., Lai, J.C., et al. Topical liposome- encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul. Immunol. Inflamm. 6:51-56, 1998.
22. Sakurai, E., Nozaki, M., Okabe, K., et al. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. 44:4845-4852, 2003.
23. Calvo, P., Vila-Jato, J.L., and Alonso, M.J. Comparative in vitro evaluation of several colloidal systems, nanospheres, and nanocapsules and nanoemulsions as ocular drug carriers. J. Pharm. Sci. 85:530-536, 1996.
24. Joshi, A. Microparticulates of ophthalmic drug delivery. J. Ocul. Pharmacol. Ther. 10:29-45, 1994.
25. Quintanar-Guarrero, D. Preparation techniques and mechanisms of formation of biodegradable nanospheres from preformed polymer. Drug Dev. Industr. Pharm. 25:1115-1123, 1998.
26. Holland, E.J., Chan, C.C., Wetzig, R.P., et al. Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea 10:374-380, 1991.
27. Urtti, A., and Salminen, L. Minimizing systemic absorption of topically administrated ophthalmic drugs. Surv. Ophthalmol. 37:435-456, 1993.
28. Kimura, H., and Ogura, Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 215:143-155, 2001.
29. Yang, P., Gong, X., Zhou, H., et al. Immunological studies on the cellular phenotype involved in corneal allograft rejection. Chin. Med. J. (Engl.) 112:202-206, 1999.